NMPA China approves Clopidogrel Bisulfate API

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹174.50

prior close

₹177.39

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-6.0% vs market

Pharmaceuticals peers, median of 165sector+0.0%-5.3% vs sector

On the reaction day the stock moved 6.0 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-1.0

15m

-0.6

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3+0.6-6.0+0.0-5.3

Next day

-5.8+0.2-5.9+0.0-5.8

-14.3-0.9-13.4-1.1-13.2

-10.9-0.3-10.6-0.4-10.5

-13.5+0.0-13.5-0.3-13.2

-15.2-1.1-14.0-1.6-13.6

-14.4-1.4-13.0-2.6-11.9

15d

-7.2+2.7-9.8-1.1-6.0

-7.7+3.6-11.3-0.4-7.2

+4.3+2.0+2.4-0.6+4.9

+11.7+1.1+10.6-2.3+14.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOL Chemicals has received approval from China's drug regulator NMPA for its API product Clopidogrel Bisulfate, used in blood-thinning medicines. This adds to the existing European CEP certification and opens direct access to the Chinese pharmaceutical market, strengthening the company's regulatory portfolio.

Likely market impact

Positive. China market access can drive new export revenue and adds a major geography to the company's API footprint beyond existing approvals.